To understand the mechanism behind pancreatic tumor regression upon treatment with engineered DCs, we employed immunohistochemistry (IHC) analysis to assess the tumor infiltration of CD4+ and CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.